ClinicalTrials.gg
CompletedNCT06215430Updated Mar 10, 2025Results posted

A Study of Effect of Multiple Doses of LOXO-305 on the Pharmacokinetics of Single Oral Doses of CYP1A2, CYP2C9, CYP2C19 Substrates in Healthy Participants

A Phase 1 interventional study of Caffeine Tablet and Omeprazole capsule in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-10.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 2 years 11 months after the study started (first participant enrolled Jan 2021, registered Dec 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The main purpose of this study is to evaluate the effect of LOXO-305 on single oral dose of caffeine cytochrome P450 1A2 (CYP1A2) substrate, S-warfarin (CYP2C9 substrate), and omeprazole (CYP2C19 substrate) when administered as multiple doses by collecting the blood samples and conducting the blood tests to measure how much LOXO-305 is in the bloodstream and how the body handles and eliminates LOXO-305 in adult healthy participants. The study will also evaluate the safety and tolerability of LOXO-305. The study will be conducted in two periods. Participants will stay in this study for up to 67 days, including screening.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have (BMI) within the range of 18.0 to 32.0 kilograms per square meter (kg/m\^2), inclusive.
  • Male and female participants in good health, determined by no findings from medical history, 12-lead (ECG), vital sign measurements, or clinical laboratory evaluations as assessed by the investigator.
  • Female participants of non- and male participants who follow standard methods.
  • Must have comply with all study procedures, including the 23-night stay at the Clinical Research Unit (CRU) and follow-up phone call.

Exclusion criteria

Exclusion Criteria:

  • History or presence of any diseases or conditions of clinical significance by the Investigator (or designee) and/or Sponsor.
  • Known ongoing alcohol and/or drug abuse within 2 years prior to Screening.
  • History of significant , intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Period 1: Probe Drug Cocktail

    Participants received 200 milligrams (mg) caffeine tablet, 40 mg omeprazole capsule, and 10 mg warfarin tablet as a single dose of probe drug cocktail, along with 10 mg vitamin K tablet on Day 1.

    Drug: Caffeine Tablet · Drug: Omeprazole capsule · Drug: Warfarin tablet

  • Experimental
    Period 2: Pirtobrutinib + Probe Drug Cocktail

    Participants received oral dose of 200 mg Pirtobrutinib once daily (QD) from Day 6 to Day 19. On Day 15, Pirtobrutinib was co-administered with 200 mg caffeine tablet, 40 mg omeprazole capsule, and 10 mg warfarin tablet as a single dose of probe drug cocktail, along with 10 mg vitamin K tablet. There was a 5-day washout period between the probe drug cocktail on Day 1 (Period 1) and the first dose of Pirtobrutinib on Day 6 (Period 2).

    Drug: Caffeine Tablet · Drug: Omeprazole capsule · Drug: Warfarin tablet · Drug: Pirtobrutinib

Interventions

  • DrugCaffeine Tablet

    Administered orally.

  • DrugOmeprazole capsule

    Administered orally.

  • DrugWarfarin tablet

    Administered orally.

  • Administered orally.

    Also known as: LOXO-305, LY3527727

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration Time Curve (AUC) From Hour 0 to 24 Hours Post-Dose (AUC0-24): Caffeine

    Area under the concentration time curve (AUC) from hour 0 to 24 hours post-dose (AUC0-24) of caffeine was reported.

    Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)

  2. Area Under the Concentration Time Curve (AUC) From Hour 0 to 24 Hours Post-Dose (AUC0-24): Paraxanthine

    AUC0-24 of Paraxanthine was reported.

    Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)

  3. Area Under the Concentration Time Curve (AUC) From Hour 0 to 24 Hours Post-Dose (AUC0-24): Omeprazole

    AUC0-24 of Omeprazole was reported.

    Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)

  4. Area Under the Concentration Time Curve (AUC) From Hour 0 to 24 Hours Post-Dose (AUC0-24): Warfarin

    AUC(0-24) of Warfarin was reported.

    Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)

  5. Area Under the Concentration Time Curve (AUC) From Hour 0 to 24 Hours Post-Dose (AUC0-24): Pirtobrutinib

    AUC0-24 of Pirtobrutinib was reported.

    Time frame: Period 2, Day 15 (0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours Post dose)

  6. Area Under the Concentration-time Curve (AUC), From Hour 0 to the Last Measurable Concentration (AUC0-t): Caffeine

    AUC from hour 0 to the last measurable concentration (AUC0-t) of caffeine was reported.

    Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)

  7. Area Under the Concentration-time Curve (AUC), From Hour 0 to the Last Measurable Concentration (AUC0-t): Paraxanthine

    AUC0-t of Paraxanthine was reported.

    Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)

  8. Area Under the Concentration Time Curve (AUC) From Hour 0 to the Last Measurable Concentration (AUC0-t): Omeprazole

    AUC0-t of Omeprazole was reported.

    Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose)

  9. Area Under the Concentration Time Curve (AUC) From Hour 0 to the Last Measurable Concentration (AUC0-t): Warfarin

    AUC0-t of Warfarin was reported.

    Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose)

  10. Area Under the Concentration Time Curve (AUC) From Hour 0 to the Last Measurable Concentration (AUC0-t): Pirtobrutinib

    AUC0-t of Pirtobrutinib was reported.

    Time frame: Period 2, Day 15 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, and 192 hours postdose)

  11. Area Under the Concentration Time Curve (AUC) From Hour 0 Extrapolated to Infinity (AUC0-inf): Caffeine

    AUC from hour 0 extrapolated to infinity (AUC0-inf) of Caffeine was reported.

    Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)

  12. Area Under the Concentration Time Curve (AUC) From Hour 0 Extrapolated to Infinity (AUC0-inf): Paraxanthine

    AUC0-inf of Paraxanthine was reported.

    Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)

  13. Area Under the Concentration Time Curve (AUC) From Hour 0 Extrapolated to Infinity (AUC0-inf): Omeprazole

    AUC0-inf of omeprazole was reported.

    Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose)

  14. Area Under the Concentration Time Curve (AUC) From Hour 0 Extrapolated to Infinity (AUC0-inf): Warfarin

    AUC0-inf of Warfarin was reported.

    Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose)

  15. Percentage Extrapolation for AUC0-inf (%AUCextrap): Caffeine

    AUC0-inf (%AUCextrap) of caffeine was reported.

    Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)

  16. Percentage Extrapolation for AUC0-inf (%AUCextrap): Paraxanthine

    AUC0-inf (%AUCextrap) of Paraxanthine was reported.

    Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)

  17. Percentage Extrapolation for AUC0-inf (%AUCextrap): Omeprazole

    %AUCextrap of omeprazole was reported.

    Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose)

  18. Percentage Extrapolation for AUC0-inf (%AUCextrap): Warfarin

    %AUCextrap of Warfarin was reported.

    Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose)

  19. Apparent Systemic Clearance (CL/F): Caffeine

    CL/F for caffeine was reported.

    Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)

  20. Apparent Systemic Clearance (CL/F): Omeprazole

    CL/F of omeprazole was reported.

    Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose)

  21. Apparent Systemic Clearance (CL/F): Warfarin

    CL/F of warfarin was reported.

    Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose)

  22. Apparent Systemic Clearance (CL/F): Pirtobrutinib

    CL/F of Pirtobrutinib was reported.

    Time frame: Period 2, Day 15 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, and 192 hours postdose)

  23. Maximum Observed Plasma Concentration (Cmax): Caffeine

    Cmax of caffeine was reported.

    Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)

  24. Maximum Observed Plasma Concentration (Cmax): Paraxanthine

    Cmax of Paraxanthine was reported.

    Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)

  25. Maximum Observed Plasma Concentration (Cmax): Omeprazole

    Cmax of omeprazole was reported.

    Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose)

  26. Maximum Observed Plasma Concentration (Cmax): Warfarin

    Cmax of warfarin was reported.

    Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose)

  27. Maximum Observed Plasma Concentration (Cmax): Pirtobrutinib

    Cmax of Pirtobrutinib was reported.

    Time frame: Period 2, Day 15 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, and 192 hours postdose)

  28. Time to Maximum Observed Plasma Concentration (Tmax): Caffeine

    Tmax of caffeine was reported.

    Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)

  29. Time to Maximum Observed Plasma Concentration (Tmax): Paraxanthine

    Tmax of Paraxanthine was reported.

    Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)

  30. Time to Maximum Observed Plasma Concentration (Tmax): Omeprazole

    Tmax of omeprazole was reported.

    Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose)

  31. Time to Maximum Observed Plasma Concentration (Tmax): Warfarin

    Tmax of warfarin was reported.

    Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose)

  32. Time to Maximum Observed Plasma Concentration (Tmax): Pirtobrutinib

    Tmax of Pirtobrutinib was reported.

    Time frame: Period 2, Day 15 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, and 192 hours postdose)

  33. Apparent Terminal Elimination Rate Constant (λZ): Caffeine

    λZ of caffeine was reported.

    Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)

  34. Apparent Terminal Elimination Rate Constant (λZ): Paraxanthine

    λZ of Paraxanthine was reported.

    Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)

  35. Apparent Terminal Elimination Rate Constant (λZ): Omeprazole

    λZ of omeprazole was reported.

    Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose)

  36. Apparent Terminal Elimination Rate Constant (λZ): Warfarin

    λZ of warfarin was reported.

    Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose)

  37. Apparent Volume of Distribution at Terminal Phase (Vz/F): Caffeine

    Vz/F of caffeine was reported.

    Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)

  38. Apparent Volume of Distribution at Terminal Phase (Vz/F): Omeprazole

    Vz/F of omeprazole was reported.

    Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose)

  39. Apparent Volume of Distribution at Terminal Phase (Vz/F): Warfarin

    Vz/F of Warfarin was reported.

    Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose)

  40. Metabolite to Parent Drug AUC Ratio (MRAUC): AUC Ratio of Paraxanthine to Caffeine

    AUC Ratio of paraxanthine (Metabolite) to caffeine (Parent drug) was reported.

    Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)

  41. Mean Residence Time (MRT): Caffeine

    MRT of caffeine was reported.

    Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)

  42. Mean Residence Time (MRT): Paraxanthine

    MRT of Paraxanthine was reported.

    Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)

  43. Mean Residence Time (MRT): Omeprazole

    MRT of omeprazole was reported.

    Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose)

  44. Mean Residence Time (MRT): Warfarin

    MRT of warfarin was reported.

    Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose)

  45. Apparent Terminal Elimination Half-Life (t1/2): Caffeine

    t1/2 of caffeine was reported.

    Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)

  46. Apparent Terminal Elimination Half-Life (t1/2): Paraxanthine

    t1/2 of Paraxanthine was reported.

    Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)

  47. Apparent Terminal Elimination Half-Life (t1/2): Omeprazole

    t1/2 of omeprazole was reported.

    Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose)

  48. Apparent Terminal Elimination Half-Life (t1/2): Warfarin

    t1/2 of warfarin was reported.

    Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose)

07

Results

Posted Mar 10, 2025

Participant flow

Period 1 (Days 1 - 5)
Participant flow — Period 1 (Days 1 - 5)
MilestonePeriod 1: Probe Drug CocktailPeriod 2: Pirtobrutinib + Probe Drug Cocktail
Started160
Received at least 1 dose of study drug160
Completed160
Not completed00
Period 2 (Days 6 - 23)
Participant flow — Period 2 (Days 6 - 23)
MilestonePeriod 1: Probe Drug CocktailPeriod 2: Pirtobrutinib + Probe Drug Cocktail
Started016
Received at least 1 dose of study drug016
Completed016
Not completed00

Outcome measures

PrimaryArea Under the Concentration Time Curve (AUC) From Hour 0 to 24 Hours Post-Dose (AUC0-24): Caffeine

Area under the concentration time curve (AUC) from hour 0 to 24 hours post-dose (AUC0-24) of caffeine was reported.

Time frame:
Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)
Reported as:
Geometric mean · hour*nanogram per milliliter (h*ng/mL)
Area Under the Concentration Time Curve (AUC) From Hour 0 to 24 Hours Post-Dose (AUC0-24): Caffeine
hour*nanogram per milliliter (h*ng/mL)Period 1: Probe Drug CocktailPeriod 2: Pirtobrutinib + Probe Drug Cocktail
Area Under the Concentration Time Curve (AUC) From Hour 0 to 24 Hours Post-Dose (AUC0-24): Caffeine39100 ± 31.837400 ± 31.8
PrimaryArea Under the Concentration Time Curve (AUC) From Hour 0 to 24 Hours Post-Dose (AUC0-24): Paraxanthine

AUC0-24 of Paraxanthine was reported.

Time frame:
Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)
Reported as:
Geometric mean · h*ng/mL
Area Under the Concentration Time Curve (AUC) From Hour 0 to 24 Hours Post-Dose (AUC0-24): Paraxanthine
h*ng/mLPeriod 1: Probe Drug CocktailPeriod 2: Pirtobrutinib + Probe Drug Cocktail
Area Under the Concentration Time Curve (AUC) From Hour 0 to 24 Hours Post-Dose (AUC0-24): Paraxanthine20600 ± 12.118600 ± 17.7
PrimaryArea Under the Concentration Time Curve (AUC) From Hour 0 to 24 Hours Post-Dose (AUC0-24): Omeprazole

AUC0-24 of Omeprazole was reported.

Time frame:
Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)
Reported as:
Geometric mean · h*ng/mL
Area Under the Concentration Time Curve (AUC) From Hour 0 to 24 Hours Post-Dose (AUC0-24): Omeprazole
h*ng/mLPeriod 1: Probe Drug CocktailPeriod 2: Pirtobrutinib + Probe Drug Cocktail
Area Under the Concentration Time Curve (AUC) From Hour 0 to 24 Hours Post-Dose (AUC0-24): Omeprazole2000 ± 100.93120 ± 61.6
PrimaryArea Under the Concentration Time Curve (AUC) From Hour 0 to 24 Hours Post-Dose (AUC0-24): Warfarin

AUC(0-24) of Warfarin was reported.

Time frame:
Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)
Reported as:
Geometric mean · h*ng/mL
Area Under the Concentration Time Curve (AUC) From Hour 0 to 24 Hours Post-Dose (AUC0-24): Warfarin
h*ng/mLPeriod 1: Probe Drug CocktailPeriod 2: Pirtobrutinib + Probe Drug Cocktail
Area Under the Concentration Time Curve (AUC) From Hour 0 to 24 Hours Post-Dose (AUC0-24): Warfarin7320 ± 19.77880 ± 18.3
PrimaryArea Under the Concentration Time Curve (AUC) From Hour 0 to 24 Hours Post-Dose (AUC0-24): Pirtobrutinib

AUC0-24 of Pirtobrutinib was reported.

Time frame:
Period 2, Day 15 (0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours Post dose)
Reported as:
Geometric mean · h*ng/mL
Area Under the Concentration Time Curve (AUC) From Hour 0 to 24 Hours Post-Dose (AUC0-24): Pirtobrutinib
h*ng/mLPeriod 2: Pirtobrutinib + Probe Drug Cocktail
Area Under the Concentration Time Curve (AUC) From Hour 0 to 24 Hours Post-Dose (AUC0-24): Pirtobrutinib119000 ± 24.4
PrimaryArea Under the Concentration-time Curve (AUC), From Hour 0 to the Last Measurable Concentration (AUC0-t): Caffeine

AUC from hour 0 to the last measurable concentration (AUC0-t) of caffeine was reported.

Time frame:
Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)
Reported as:
Geometric mean · h*ng/mL
Area Under the Concentration-time Curve (AUC), From Hour 0 to the Last Measurable Concentration (AUC0-t): Caffeine
h*ng/mLPeriod 1: Probe Drug CocktailPeriod 2: Pirtobrutinib + Probe Drug Cocktail
Area Under the Concentration-time Curve (AUC), From Hour 0 to the Last Measurable Concentration (AUC0-t): Caffeine39100 ± 31.837400 ± 31.7
PrimaryArea Under the Concentration-time Curve (AUC), From Hour 0 to the Last Measurable Concentration (AUC0-t): Paraxanthine

AUC0-t of Paraxanthine was reported.

Time frame:
Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)
Reported as:
Geometric mean · h*ng/mL
Area Under the Concentration-time Curve (AUC), From Hour 0 to the Last Measurable Concentration (AUC0-t): Paraxanthine
h*ng/mLPeriod 1: Probe Drug CocktailPeriod 2: Pirtobrutinib + Probe Drug Cocktail
Area Under the Concentration-time Curve (AUC), From Hour 0 to the Last Measurable Concentration (AUC0-t): Paraxanthine20600 ± 12.119400 ± 14.0
PrimaryArea Under the Concentration Time Curve (AUC) From Hour 0 to the Last Measurable Concentration (AUC0-t): Omeprazole

AUC0-t of Omeprazole was reported.

Time frame:
Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose)
Reported as:
Geometric mean · h*ng/mL
Area Under the Concentration Time Curve (AUC) From Hour 0 to the Last Measurable Concentration (AUC0-t): Omeprazole
h*ng/mLPeriod 1: Probe Drug CocktailPeriod 2: Pirtobrutinib + Probe Drug Cocktail
Area Under the Concentration Time Curve (AUC) From Hour 0 to the Last Measurable Concentration (AUC0-t): Omeprazole1990 ± 101.03110 ± 61.7
PrimaryArea Under the Concentration Time Curve (AUC) From Hour 0 to the Last Measurable Concentration (AUC0-t): Warfarin

AUC0-t of Warfarin was reported.

Time frame:
Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose)
Reported as:
Geometric mean · h*ng/mL
Area Under the Concentration Time Curve (AUC) From Hour 0 to the Last Measurable Concentration (AUC0-t): Warfarin
h*ng/mLPeriod 1: Probe Drug CocktailPeriod 2: Pirtobrutinib + Probe Drug Cocktail
Area Under the Concentration Time Curve (AUC) From Hour 0 to the Last Measurable Concentration (AUC0-t): Warfarin17300 ± 19.119200 ± 20.0
PrimaryArea Under the Concentration Time Curve (AUC) From Hour 0 to the Last Measurable Concentration (AUC0-t): Pirtobrutinib

AUC0-t of Pirtobrutinib was reported.

Time frame:
Period 2, Day 15 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, and 192 hours postdose)
Reported as:
Geometric mean · h*ng/mL
Area Under the Concentration Time Curve (AUC) From Hour 0 to the Last Measurable Concentration (AUC0-t): Pirtobrutinib
h*ng/mLPeriod 2: Pirtobrutinib + Probe Drug Cocktail
Area Under the Concentration Time Curve (AUC) From Hour 0 to the Last Measurable Concentration (AUC0-t): Pirtobrutinib119000 ± 24.4
PrimaryArea Under the Concentration Time Curve (AUC) From Hour 0 Extrapolated to Infinity (AUC0-inf): Caffeine

AUC from hour 0 extrapolated to infinity (AUC0-inf) of Caffeine was reported.

Time frame:
Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)
Reported as:
Geometric mean · h*ng/mL
Area Under the Concentration Time Curve (AUC) From Hour 0 Extrapolated to Infinity (AUC0-inf): Caffeine
h*ng/mLPeriod 1: Probe Drug CocktailPeriod 2: Pirtobrutinib + Probe Drug Cocktail
Area Under the Concentration Time Curve (AUC) From Hour 0 Extrapolated to Infinity (AUC0-inf): Caffeine42600 ± 39.740000 ± 37.5
PrimaryArea Under the Concentration Time Curve (AUC) From Hour 0 Extrapolated to Infinity (AUC0-inf): Paraxanthine

AUC0-inf of Paraxanthine was reported.

Time frame:
Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)
Reported as:
Geometric mean · h*ng/mL
Area Under the Concentration Time Curve (AUC) From Hour 0 Extrapolated to Infinity (AUC0-inf): Paraxanthine
h*ng/mLPeriod 1: Probe Drug CocktailPeriod 2: Pirtobrutinib + Probe Drug Cocktail
Area Under the Concentration Time Curve (AUC) From Hour 0 Extrapolated to Infinity (AUC0-inf): Paraxanthine23100 ± 10.120300 ± 17.4
PrimaryArea Under the Concentration Time Curve (AUC) From Hour 0 Extrapolated to Infinity (AUC0-inf): Omeprazole

AUC0-inf of omeprazole was reported.

Time frame:
Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose)
Reported as:
Geometric mean · h*ng/mL
Area Under the Concentration Time Curve (AUC) From Hour 0 Extrapolated to Infinity (AUC0-inf): Omeprazole
h*ng/mLPeriod 1: Probe Drug CocktailPeriod 2: Pirtobrutinib + Probe Drug Cocktail
Area Under the Concentration Time Curve (AUC) From Hour 0 Extrapolated to Infinity (AUC0-inf): Omeprazole2000 ± 101.03120 ± 61.6
PrimaryArea Under the Concentration Time Curve (AUC) From Hour 0 Extrapolated to Infinity (AUC0-inf): Warfarin

AUC0-inf of Warfarin was reported.

Time frame:
Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose)
Reported as:
Geometric mean · h*ng/mL
Area Under the Concentration Time Curve (AUC) From Hour 0 Extrapolated to Infinity (AUC0-inf): Warfarin
h*ng/mLPeriod 1: Probe Drug CocktailPeriod 2: Pirtobrutinib + Probe Drug Cocktail
Area Under the Concentration Time Curve (AUC) From Hour 0 Extrapolated to Infinity (AUC0-inf): Warfarin20100 ± 21.122400 ± 21.9
PrimaryPercentage Extrapolation for AUC0-inf (%AUCextrap): Caffeine

AUC0-inf (%AUCextrap) of caffeine was reported.

Time frame:
Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)
Reported as:
Geometric mean · percentage of AUCextrap
Percentage Extrapolation for AUC0-inf (%AUCextrap): Caffeine
percentage of AUCextrapPeriod 1: Probe Drug CocktailPeriod 2: Pirtobrutinib + Probe Drug Cocktail
Percentage Extrapolation for AUC0-inf (%AUCextrap): Caffeine5.20 ± 130.64.17 ± 149.3
PrimaryPercentage Extrapolation for AUC0-inf (%AUCextrap): Paraxanthine

AUC0-inf (%AUCextrap) of Paraxanthine was reported.

Time frame:
Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)
Reported as:
Geometric mean · percentage of AUCextrap
Percentage Extrapolation for AUC0-inf (%AUCextrap): Paraxanthine
percentage of AUCextrapPeriod 1: Probe Drug CocktailPeriod 2: Pirtobrutinib + Probe Drug Cocktail
Percentage Extrapolation for AUC0-inf (%AUCextrap): Paraxanthine12.0 ± 58.37.45 ± 63.6
PrimaryPercentage Extrapolation for AUC0-inf (%AUCextrap): Omeprazole

%AUCextrap of omeprazole was reported.

Time frame:
Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose)
Reported as:
Geometric mean · percentage of AUCextrap
Percentage Extrapolation for AUC0-inf (%AUCextrap): Omeprazole
percentage of AUCextrapPeriod 1: Probe Drug CocktailPeriod 2: Pirtobrutinib + Probe Drug Cocktail
Percentage Extrapolation for AUC0-inf (%AUCextrap): Omeprazole0.421 ± 84.30.302 ± 97.8
PrimaryPercentage Extrapolation for AUC0-inf (%AUCextrap): Warfarin

%AUCextrap of Warfarin was reported.

Time frame:
Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose)
Reported as:
Geometric mean · percentage of AUCextrap
Percentage Extrapolation for AUC0-inf (%AUCextrap): Warfarin
percentage of AUCextrapPeriod 1: Probe Drug CocktailPeriod 2: Pirtobrutinib + Probe Drug Cocktail
Percentage Extrapolation for AUC0-inf (%AUCextrap): Warfarin13.1 ± 33.513.4 ± 32.7
PrimaryApparent Systemic Clearance (CL/F): Caffeine

CL/F for caffeine was reported.

Time frame:
Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)
Reported as:
Geometric mean · Liter per hour (L/h)
Apparent Systemic Clearance (CL/F): Caffeine
Liter per hour (L/h)Period 1: Probe Drug CocktailPeriod 2: Pirtobrutinib + Probe Drug Cocktail
Apparent Systemic Clearance (CL/F): Caffeine4.70 ± 39.75.00 ± 37.5
PrimaryApparent Systemic Clearance (CL/F): Omeprazole

CL/F of omeprazole was reported.

Time frame:
Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose)
Reported as:
Geometric mean · L/h
Apparent Systemic Clearance (CL/F): Omeprazole
L/hPeriod 1: Probe Drug CocktailPeriod 2: Pirtobrutinib + Probe Drug Cocktail
Apparent Systemic Clearance (CL/F): Omeprazole20.0 ± 101.012.8 ± 61.6
PrimaryApparent Systemic Clearance (CL/F): Warfarin

CL/F of warfarin was reported.

Time frame:
Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose)
Reported as:
Geometric mean · L/h
Apparent Systemic Clearance (CL/F): Warfarin
L/hPeriod 1: Probe Drug CocktailPeriod 2: Pirtobrutinib + Probe Drug Cocktail
Apparent Systemic Clearance (CL/F): Warfarin0.497 ± 21.10.447 ± 21.9
PrimaryApparent Systemic Clearance (CL/F): Pirtobrutinib

CL/F of Pirtobrutinib was reported.

Time frame:
Period 2, Day 15 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, and 192 hours postdose)
Reported as:
Geometric mean · L/h
Apparent Systemic Clearance (CL/F): Pirtobrutinib
L/hPirtobrutinib 200 mg QD + Probe Drug Cocktail
Apparent Systemic Clearance (CL/F): Pirtobrutinib1.68 ± 24.4
PrimaryMaximum Observed Plasma Concentration (Cmax): Caffeine

Cmax of caffeine was reported.

Time frame:
Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax): Caffeine
ng/mLPeriod 1: Probe Drug CocktailPeriod 2: Pirtobrutinib + Probe Drug Cocktail
Maximum Observed Plasma Concentration (Cmax): Caffeine5060 ± 17.64990 ± 14.5
PrimaryMaximum Observed Plasma Concentration (Cmax): Paraxanthine

Cmax of Paraxanthine was reported.

Time frame:
Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax): Paraxanthine
ng/mLPeriod 1: Probe Drug CocktailPeriod 2: Pirtobrutinib + Probe Drug Cocktail
Maximum Observed Plasma Concentration (Cmax): Paraxanthine1200 ± 14.31150 ± 14.6
PrimaryMaximum Observed Plasma Concentration (Cmax): Omeprazole

Cmax of omeprazole was reported.

Time frame:
Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose)
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax): Omeprazole
ng/mLPeriod 1: Probe Drug CocktailPeriod 2: Pirtobrutinib + Probe Drug Cocktail
Maximum Observed Plasma Concentration (Cmax): Omeprazole901 ± 58.01350 ± 42.3
PrimaryMaximum Observed Plasma Concentration (Cmax): Warfarin

Cmax of warfarin was reported.

Time frame:
Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose)
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax): Warfarin
ng/mLPeriod 1: Probe Drug CocktailPeriod 2: Pirtobrutinib + Probe Drug Cocktail
Maximum Observed Plasma Concentration (Cmax): Warfarin585 ± 26.1595 ± 25.2
PrimaryMaximum Observed Plasma Concentration (Cmax): Pirtobrutinib

Cmax of Pirtobrutinib was reported.

Time frame:
Period 2, Day 15 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, and 192 hours postdose)
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax): Pirtobrutinib
ng/mLPeriod 2: Pirtobrutinib + Probe Drug Cocktail
Maximum Observed Plasma Concentration (Cmax): Pirtobrutinib9430 ± 24.6
PrimaryTime to Maximum Observed Plasma Concentration (Tmax): Caffeine

Tmax of caffeine was reported.

Time frame:
Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)
Reported as:
Median · hour (h)
Time to Maximum Observed Plasma Concentration (Tmax): Caffeine
hour (h)Period 1: Probe Drug CocktailPeriod 2: Pirtobrutinib + Probe Drug Cocktail
Time to Maximum Observed Plasma Concentration (Tmax): Caffeine0.500 (0.500 to 1.00)0.750 (0.500 to 1.00)
PrimaryTime to Maximum Observed Plasma Concentration (Tmax): Paraxanthine

Tmax of Paraxanthine was reported.

Time frame:
Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)
Reported as:
Median · hour (h)
Time to Maximum Observed Plasma Concentration (Tmax): Paraxanthine
hour (h)Period 1: Probe Drug CocktailPeriod 2: Pirtobrutinib + Probe Drug Cocktail
Time to Maximum Observed Plasma Concentration (Tmax): Paraxanthine10.0 (6.00 to 24.0)8.01 (6.00 to 12.0)
PrimaryTime to Maximum Observed Plasma Concentration (Tmax): Omeprazole

Tmax of omeprazole was reported.

Time frame:
Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose)
Reported as:
Median · hour (h)
Time to Maximum Observed Plasma Concentration (Tmax): Omeprazole
hour (h)Period 1: Probe Drug CocktailPeriod 2: Pirtobrutinib + Probe Drug Cocktail
Time to Maximum Observed Plasma Concentration (Tmax): Omeprazole2.00 (1.50 to 4.00)2.50 (1.50 to 4.00)
PrimaryTime to Maximum Observed Plasma Concentration (Tmax): Warfarin

Tmax of warfarin was reported.

Time frame:
Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose)
Reported as:
Median · hour (h)
Time to Maximum Observed Plasma Concentration (Tmax): Warfarin
hour (h)Period 1: Probe Drug CocktailPeriod 2: Pirtobrutinib + Probe Drug Cocktail
Time to Maximum Observed Plasma Concentration (Tmax): Warfarin1.50 (0.500 to 3.00)1.50 (0.250 to 3.00)
PrimaryTime to Maximum Observed Plasma Concentration (Tmax): Pirtobrutinib

Tmax of Pirtobrutinib was reported.

Time frame:
Period 2, Day 15 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, and 192 hours postdose)
Reported as:
Median · hour (h)
Time to Maximum Observed Plasma Concentration (Tmax): Pirtobrutinib
hour (h)Period 2: Pirtobrutinib + Probe Drug Cocktail
Time to Maximum Observed Plasma Concentration (Tmax): Pirtobrutinib2.50 (0.767 to 4.00)
PrimaryApparent Terminal Elimination Rate Constant (λZ): Caffeine

λZ of caffeine was reported.

Time frame:
Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)
Reported as:
Geometric least squares mean · 1/hour (1/h)
Apparent Terminal Elimination Rate Constant (λZ): Caffeine
1/hour (1/h)Period 1: Probe Drug CocktailPeriod 2: Pirtobrutinib + Probe Drug Cocktail
Apparent Terminal Elimination Rate Constant (λZ): Caffeine0.116 ± 37.80.127 ± 34.6
PrimaryApparent Terminal Elimination Rate Constant (λZ): Paraxanthine

λZ of Paraxanthine was reported.

Time frame:
Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)
Reported as:
Geometric mean · 1/hour (1/h)
Apparent Terminal Elimination Rate Constant (λZ): Paraxanthine
1/hour (1/h)Period 1: Probe Drug CocktailPeriod 2: Pirtobrutinib + Probe Drug Cocktail
Apparent Terminal Elimination Rate Constant (λZ): Paraxanthine0.0966 ± 24.00.120 ± 21.8
PrimaryApparent Terminal Elimination Rate Constant (λZ): Omeprazole

λZ of omeprazole was reported.

Time frame:
Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose)
Reported as:
Geometric mean · 1/hour (1/h)
Apparent Terminal Elimination Rate Constant (λZ): Omeprazole
1/hour (1/h)Period 1: Probe Drug CocktailPeriod 2: Pirtobrutinib + Probe Drug Cocktail
Apparent Terminal Elimination Rate Constant (λZ): Omeprazole0.611 ± 48.40.578 ± 37.2
PrimaryApparent Terminal Elimination Rate Constant (λZ): Warfarin

λZ of warfarin was reported.

Time frame:
Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose)
Reported as:
Geometric mean · 1/hour (1/h)
Apparent Terminal Elimination Rate Constant (λZ): Warfarin
1/hour (1/h)Period 1: Probe Drug CocktailPeriod 2: Pirtobrutinib + Probe Drug Cocktail
Apparent Terminal Elimination Rate Constant (λZ): Warfarin0.0160 ± 17.10.0165 ± 16.4
PrimaryApparent Volume of Distribution at Terminal Phase (Vz/F): Caffeine

Vz/F of caffeine was reported.

Time frame:
Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)
Reported as:
Geometric mean · Litre (L)
Apparent Volume of Distribution at Terminal Phase (Vz/F): Caffeine
Litre (L)Period 1: Probe Drug CocktailPeriod 2: Pirtobrutinib + Probe Drug Cocktail
Apparent Volume of Distribution at Terminal Phase (Vz/F): Caffeine40.4 ± 16.839.4 ± 18.1
PrimaryApparent Volume of Distribution at Terminal Phase (Vz/F): Omeprazole

Vz/F of omeprazole was reported.

Time frame:
Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose)
Reported as:
Geometric mean · Litre (L)
Apparent Volume of Distribution at Terminal Phase (Vz/F): Omeprazole
Litre (L)Period 1: Probe Drug CocktailPeriod 2: Pirtobrutinib + Probe Drug Cocktail
Apparent Volume of Distribution at Terminal Phase (Vz/F): Omeprazole32.8 ± 45.722.2 ± 33.6
PrimaryApparent Volume of Distribution at Terminal Phase (Vz/F): Warfarin

Vz/F of Warfarin was reported.

Time frame:
Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose)
Reported as:
Geometric mean · Litre (L)
Apparent Volume of Distribution at Terminal Phase (Vz/F): Warfarin
Litre (L)Period 1: Probe Drug CocktailPeriod 2: Pirtobrutinib + Probe Drug Cocktail
Apparent Volume of Distribution at Terminal Phase (Vz/F): Warfarin31.0 ± 18.427.1 ± 21.0
PrimaryMetabolite to Parent Drug AUC Ratio (MRAUC): AUC Ratio of Paraxanthine to Caffeine

AUC Ratio of paraxanthine (Metabolite) to caffeine (Parent drug) was reported.

Time frame:
Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)
Reported as:
Geometric mean · Ratio
Metabolite to Parent Drug AUC Ratio (MRAUC): AUC Ratio of Paraxanthine to Caffeine
RatioPeriod 1: Probe Drug CocktailPeriod 2: Pirtobrutinib + Probe Drug Cocktail
Metabolite to Parent Drug AUC Ratio (MRAUC): AUC Ratio of Paraxanthine to Caffeine0.528 ± 29.10.518 ± 27.8
PrimaryMean Residence Time (MRT): Caffeine

MRT of caffeine was reported.

Time frame:
Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)
Reported as:
Geometric mean · hour (h)
Mean Residence Time (MRT): Caffeine
hour (h)Period 1: Probe Drug CocktailPeriod 2: Pirtobrutinib + Probe Drug Cocktail
Mean Residence Time (MRT): Caffeine8.58 ± 35.88.03 ± 30.9
PrimaryMean Residence Time (MRT): Paraxanthine

MRT of Paraxanthine was reported.

Time frame:
Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)
Reported as:
Geometric mean · hour (h)
Mean Residence Time (MRT): Paraxanthine
hour (h)Period 1: Probe Drug CocktailPeriod 2: Pirtobrutinib + Probe Drug Cocktail
Mean Residence Time (MRT): Paraxanthine12.8 ± 18.310.9 ± 14.8
PrimaryMean Residence Time (MRT): Omeprazole

MRT of omeprazole was reported.

Time frame:
Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose)
Reported as:
Geometric mean · hour (h)
Mean Residence Time (MRT): Omeprazole
hour (h)Period 1: Probe Drug CocktailPeriod 2: Pirtobrutinib + Probe Drug Cocktail
Mean Residence Time (MRT): Omeprazole3.22 ± 32.43.58 ± 20.1
PrimaryMean Residence Time (MRT): Warfarin

MRT of warfarin was reported.

Time frame:
Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose)
Reported as:
Geometric mean · hour (h)
Mean Residence Time (MRT): Warfarin
hour (h)Period 1: Probe Drug CocktailPeriod 2: Pirtobrutinib + Probe Drug Cocktail
Mean Residence Time (MRT): Warfarin56.8 ± 18.957.9 ± 18.7
PrimaryApparent Terminal Elimination Half-Life (t1/2): Caffeine

t1/2 of caffeine was reported.

Time frame:
Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)
Reported as:
Geometric mean · hour (h)
Apparent Terminal Elimination Half-Life (t1/2): Caffeine
hour (h)Period 1: Probe Drug CocktailPeriod 2: Pirtobrutinib + Probe Drug Cocktail
Apparent Terminal Elimination Half-Life (t1/2): Caffeine5.96 ± 37.85.47 ± 34.6
PrimaryApparent Terminal Elimination Half-Life (t1/2): Paraxanthine

t1/2 of Paraxanthine was reported.

Time frame:
Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)
Reported as:
Geometric mean · hour (h)
Apparent Terminal Elimination Half-Life (t1/2): Paraxanthine
hour (h)Period 1: Probe Drug CocktailPeriod 2: Pirtobrutinib + Probe Drug Cocktail
Apparent Terminal Elimination Half-Life (t1/2): Paraxanthine7.17 ± 24.05.79 ± 21.8
PrimaryApparent Terminal Elimination Half-Life (t1/2): Omeprazole

t1/2 of omeprazole was reported.

Time frame:
Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose)
Reported as:
Geometric mean · hour (h)
Apparent Terminal Elimination Half-Life (t1/2): Omeprazole
hour (h)Period 1: Probe Drug CocktailPeriod 2: Pirtobrutinib + Probe Drug Cocktail
Apparent Terminal Elimination Half-Life (t1/2): Omeprazole1.13 ± 48.41.20 ± 37.2
PrimaryApparent Terminal Elimination Half-Life (t1/2): Warfarin

t1/2 of warfarin was reported.

Time frame:
Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose)
Reported as:
Geometric mean · hour (h)
Apparent Terminal Elimination Half-Life (t1/2): Warfarin
hour (h)Period 1: Probe Drug CocktailPeriod 2: Pirtobrutinib + Probe Drug Cocktail
Apparent Terminal Elimination Half-Life (t1/2): Warfarin43.2 ± 17.142.0 ± 16.4

Adverse events

Collected over From Baseline up to End of Study i.e. 30 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Probe Drug Cocktail0/16 (0%)0/16 (0%)3/16 (18.8%)
Pirtobrutinib 200 mg QD0/16 (0%)0/16 (0%)8/16 (50%)
Pirtobrutinib 200 mg QD + Probe Drug Cocktail0/16 (0%)0/16 (0%)1/16 (6.3%)
Most frequent other events
Most frequent other events
EventProbe Drug CocktailPirtobrutinib 200 mg QDPirtobrutinib 200 mg QD + Probe Drug Cocktail
PetechiaeSkin and subcutaneous tissue disorders0/165/160/16
CheilitisGastrointestinal disorders0/161/160/16
Vessel puncture site painGeneral disorders0/161/160/16
Seasonal allergyImmune system disorders1/160/160/16
Back painMusculoskeletal and connective tissue disorders1/160/160/16
CostochondritisMusculoskeletal and connective tissue disorders0/160/161/16
DizzinessNervous system disorders1/160/160/16
HeadacheNervous system disorders0/161/160/16
CoughRespiratory, thoracic and mediastinal disorders1/161/160/16
RhinorrhoeaRespiratory, thoracic and mediastinal disorders1/161/160/16

Baseline characteristics

All participants who received at least one dose of the study drug.

Age, Continuous
Age, Continuous(years)Overall Study Participants
Mean39.1 ± 9.46
Sex: Female, Male
Sex: Female, Male(Participants)Overall Study Participants
Female4
Male12
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Overall Study Participants
Hispanic or Latino4
Not Hispanic or Latino12
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Overall Study Participants
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American7
White9
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Overall Study Participants
United States16
08

Study locations

1 site
  • Covance Clinical Research Unit
    Dallas, Texas 75247, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2021 to primary completion in Apr 2021, 3 months.

Results were first posted in Mar 2025, 3 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2023
First posted
Jan 22, 2024
StartActual
Jan 11, 2021
Primary completionActual
Apr 15, 2021
CompletionActual
Apr 15, 2021
Results first posted
Mar 10, 2025
Last update
Mar 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06215430
Collaborators
Loxo Oncology, Inc.
Responsible party
Sponsor
First posted
Jan 22, 2024
Start date
Jan 11, 2021
Primary completion
Apr 15, 2021
Completion
Apr 15, 2021
Results posted
Mar 10, 2025
Last update
Mar 10, 2025

Study contacts

Renee Ward, MD, PhD
study director · Loxo Oncology, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pirtobrutinib

Start the discussion